Last reviewed · How we verify
Individual ATG
ATG (anti-thymocyte globulin) is a polyclonal antibody that depletes T lymphocytes to suppress immune responses.
ATG (anti-thymocyte globulin) is a polyclonal antibody that depletes T lymphocytes to suppress immune responses. Used for Prevention of acute organ rejection in renal transplant recipients, Treatment of acute rejection episodes in transplant recipients, Aplastic anemia.
At a glance
| Generic name | Individual ATG |
|---|---|
| Sponsor | The First Affiliated Hospital of Soochow University |
| Drug class | Polyclonal antithymocyte globulin (immunosuppressant) |
| Target | T lymphocytes (CD2, CD3, CD4, CD8, CD25 antigens) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
ATG binds to and eliminates T cells, which are key drivers of immune-mediated rejection and autoimmune disease. By reducing circulating T lymphocytes, it prevents graft rejection in transplant recipients and suppresses pathogenic immune responses in autoimmune conditions. The mechanism involves both direct cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC).
Approved indications
- Prevention of acute organ rejection in renal transplant recipients
- Treatment of acute rejection episodes in transplant recipients
- Aplastic anemia
Common side effects
- Fever
- Chills
- Leukopenia
- Thrombocytopenia
- Infection
- Serum sickness
Key clinical trials
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
- Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (PHASE2)
- Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (PHASE1, PHASE2)
- Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation (PHASE3)
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
- ATG Individualized Dosing Model in URD-PBSCT. (PHASE2)
- Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
- Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Individual ATG CI brief — competitive landscape report
- Individual ATG updates RSS · CI watch RSS
- The First Affiliated Hospital of Soochow University portfolio CI